Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 12/2013

01.12.2013 | Stroke (C Sila, Section Editor)

Cerebral Microbleeds and Macrobleeds: Should They Influence Our Recommendations for Antithrombotic Therapies?

verfasst von: Kellen E. Haley, Steven M. Greenberg, M. Edip Gurol

Erschienen in: Current Cardiology Reports | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Intracerebral hemorrhage (ICH, or macrobleeds) and cerebral microbleeds—smaller foci of hemosiderin deposits commonly detected by magnetic resonance imaging of older adults with or without ICH—are both associated with an increased risk of future ICH. These hemorrhagic pathologies also share risk factors with ischemic thromboembolic conditions that may require antithrombotic therapy, requiring specialists in cardiology, internal medicine, and neurology to weigh the benefits vs hemorrhagic risks of antithrombotics in individual patients. This paper will review recent advances in our understanding of hemorrhage prone cerebrovascular pathologies with a particular emphasis on use of these markers in decision making for antithrombotic use.
Literatur
1.
Massaro AR, Sacco RL, Mohr JP, et al. Clinical discriminators of lobar and deep hemorrhages: the Stroke Data Bank. Neurology. 1991;41:1881–5.PubMedCrossRef
2.
Gurol ME, Greenberg SM. Management of intracerebral hemorrhage. Curr Atheroscler Rep. 2008;10:324–31.PubMedCrossRef
3.
Greenberg SM, Nandigam RN, Delgado P, et al. Microbleeds vs macrobleeds: evidence for distinct entities. Stroke. 2009;40:2382–6.PubMedCrossRef
4.
•• van Asch CJJ, Luitse MJA, Rinkel GE, van der Tweel I, Algra A, Klijn CJM. Incidence, case fatality, and functional outcome of intracerebral haemorrhage overtime, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167–76. Recent good quality systematic review of ICH epidemiology and prognosis. PubMedCrossRef
5.
Russell MW, Boulanger L, Joshi AV, Neumann PJ, Menzin J. The economic burden of intracerebral hemorrhage: evidence from managed care. Manag Care Interface. 2006;19:24–8, 34.
6.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.PubMedCrossRef
7.
Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–21.PubMedCrossRef
8.
Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880–4.PubMedCrossRef
9.
Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–64.PubMedCrossRef
10.
Greenberg SM, Finklestein SP, Schaefer PW. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology. 1996;46:1751–4.PubMedCrossRef
11.
Soo YO, Yang SR, Lam WW, et al. Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. J Neurol. 2008;255:1679–86.PubMedCrossRef
12.
Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke. 2010;41(10 Suppl):S103–6.PubMedCrossRef
13.
Lovelock CE, Cordonnier C, Naka H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke. 2010;41:1222–8.PubMedCrossRef
14.
Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34:1710–6.PubMedCrossRef
15.
Gurol ME. Cerebral amyloid angiopathy. Turk J Neurol. 2009;15:1–9.
16.
Smith EE, Vijayappa M, Lima F, et al. Impaired visual evoked flow velocity response in cerebral amyloid angiopathy. Neurology. 2008;71:1424–30.PubMedCrossRef
17.
Gurol ME, Viswanathan A, Gidicsin C, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol. 2013;73:529–36.CrossRef
18.
Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol. 2009;9:3.PubMedCrossRef
19.
Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol. 2011;69:320–7.PubMedCrossRef
20.
Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke. 2004;35:1415–20.PubMedCrossRef
21.
Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537–9.PubMedCrossRef
22.
Smith EE, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Curr Atheroscler Rep. 2003;5:260–6.PubMedCrossRef
23.
Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74:1346–50.PubMedCrossRef
24.
Castellanos M, Leira R, Tejada J, Gil-Peralta A, Davalos A, Castillo J. Predictors of good outcome in medium to large spontaneous supratentorial intracerebral haemorrhages. J Neurol Neurosurg Psychiatry. 2005;76:691–5.PubMedCrossRef
25.
Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology. 2000;55:947–51.PubMedCrossRef
26.
Arima H, Tzourio C, Anderson C, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke. 2010;41:394–6.PubMedCrossRef
27.
Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. Stroke. 1996;27:2020–5.PubMedCrossRef
28.
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.PubMedCrossRef
29.
Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144–52.PubMedCrossRef
30.
Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999;53:1319–27.PubMedCrossRef
31.
Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002;59:193–7.PubMedCrossRef
32.
Biffi A, Halpin A, Towfighi A, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2010;75:693–8.PubMedCrossRef
33.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.PubMedCrossRef
34.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.PubMedCrossRef
35.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.PubMedCrossRef
36.
• Lubitz SA, Bauer KA, Benjamin EJ, et al. Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation. A summary of an American Federation of Aging Research Seminar. J Am Geriatr Soc. 2013. doi:10.​1111/​jgs.​12456. Good overview of both established and emerging stroke prevention strategies in patients with atrial fibrillation.
37.
Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman Device in patients with a contraindication for oral anticoagulation: ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology (ASAP Study). J Am Coll Cardiol. 2013;61(25):2551–6.
38.
Massumi A, Chelu MG, Nazeri A, et al. Initial experience with a novel percutaneous left atrial appendage exclusion device in patients with atrial fibrillation, increased stroke risk, and contraindications to anticoagulation. Am J Cardiol. 2013;111:869–73.PubMedCrossRef
39.
Viswanathan A, Rakich SM, Engel C, et al. Antiplatelet use after intracerebral hemorrhage. Neurology. 2006;66:206–9.PubMedCrossRef
40.
Juvela S, Hillbom M, Palomäki H. Risk factors for spontaneous intracerebral hemorrhage. Stroke. 1995;26:1558–64.PubMedCrossRef
41.
Zacharia BE, Vaughan KA, Jacoby A, Hickman ZL, Bodmer D, Connolly ES. Management of ruptured brain arteriovenous malformations. Curr Atheroscler Rep. 2012;14:335–42.PubMedCrossRef
42.
Jellinger KA, Mitter-Ferstl E. The impact of cerebrovascular lesions in Alzheimer disease–a comparative autopsy study. J Neurol. 2003;250:1050–5.PubMedCrossRef
43.
Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165–74.PubMedCrossRef
44.
Lee SH, Bae HJ, Kwon SJ, et al. Cerebral microbleeds are regionally associated with intracerebral hemorrhage. Neurology. 2004;62:72–6.PubMedCrossRef
45.
Lee SH, Ryu WS, Roh JK. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology. 2009;72:171–6.PubMedCrossRef
46.
van Etten ES, Auriel E, Haley KE, McNamara KA, Ayres AM, Vashkevich A, et al. Warfarin increases risk of future intracerebral hemorrhage in patients presenting with isolated lobar microbleeds on MRI. Stroke 2013;44: Abstract TP301.
47.
Poels MM, Ikram MA, van der Lugt A, et al. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study. Neurology. 2012;78:326–33.PubMedCrossRef
48.
Smith EE, Nandigam KR, Chen YW, et al. MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage. Stroke. 2010;41:1933–8.PubMedCrossRef
49.
Holland CM, Smith EE, Csapo I, et al. Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke. 2008;39:1127–33.PubMedCrossRef
50.
Smith EE, Gurol ME, Eng JA, et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology. 2004;63:1606–12.PubMedCrossRef
51.
Chen YW, Gurol ME, Rosand J, et al. Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology. 2006;67:83–7.PubMedCrossRef
52.
Rostrup E, Gouw AA, Vrenken H, et al. The spatial distribution of age-related white matter changes as a function of vascular risk factors—results from the LADIS study. Neuroimage. 2012;60:1597–607.PubMedCrossRef
53.
Linn J, Wollenweber FA, Lummel N, et al. Superficial siderosis is a warning sign for future intracranial hemorrhage. J Neurol. 2013;260:176–81.PubMedCrossRef
54.
•• Charidimou A, Peeters A, Fox Z, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multi-center magnetic resonance imaging cohort study and meta-analysis. Stroke. 2012;43:2324–30. A nice review of transient focal deficits in CAA patients including their correlations with imaging findings and prognostic significance. PubMedCrossRef
55.
Barreto RD, Ruano L, Cruz VT, Veira C, Coutinho P. Superficial siderosis and anticoagulation therapy: different presentations, different outcomes. Case Rep Neurol Med. 2012;2012:745430.PubMed
56.
Greenberg SM, Briggs ME, Hyman BT, et al. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke. 1996;27:1333–7.PubMedCrossRef
57.
Greenberg SM, Vonsattel JP, Segal AZ, et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology. 1998;50:961–5.PubMedCrossRef
58.
O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000;342:240–5.PubMedCrossRef
59.
Biffi A, Sonni A, Anderson CD, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol. 2010;68:934–43.PubMedCrossRef
60.
Eckman MH, Wong LK, Soo YO, et al. Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help? Stroke. 2008;39:3308–15.PubMedCrossRef
61.
Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229–34.PubMedCrossRef
62.
Greenberg SM, Grabowski T, Gurol ME, et al. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol. 2008;64:587–91.PubMedCrossRef
63.
•• Gurol ME, Dierksen G, Betensky R, et al. Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology. 2012;79:320–6. Longitudinal study that suggests a potential role of amyloid imaging to predict risk of future ICH in CAA patients. PubMedCrossRef
Metadaten
Titel
Cerebral Microbleeds and Macrobleeds: Should They Influence Our Recommendations for Antithrombotic Therapies?
verfasst von
Kellen E. Haley
Steven M. Greenberg
M. Edip Gurol
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 12/2013
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-013-0425-8

Weitere Artikel der Ausgabe 12/2013

Current Cardiology Reports 12/2013 Zur Ausgabe

Stroke (C Sila, Section Editor)

The Challenge of Stroke Prevention with Intracranial Arterial Stenosis

Stroke (C Sila, Section Editor)

The Growing Problem of Stroke among Young Adults

Stroke (C Sila, Section Editor)

Cryptogenic Stroke: How to Define It? How to Treat It?

Hypertension (M Sorrentino, Section Editor)

Medical Treatment of Hypertension in Patients with Heart Failure with Preserved Ejection Fraction

Stroke (C Sila, Section Editor)

Acute Hypertensive Response Management in Patients with Acute Stroke

Stroke (C Sila, Section Editor)

Small Vessel Disease and Memory Loss: What the Clinician Needs to Know to Preserve Patients’ Brain Health

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise